Who should not use pioglitazone? Allergies to Ingredients. People who are allergic to any of the following should not take pioglitazone. Pioglitazone; Actos; Any other medicine that contains
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
What should I discuss with my healthcare provider before taking pioglitazone? You should not use this medicine if you are allergic to pioglitazone, or if you
Patients who take pioglitazone should be closely monitored for signs of heart failure; treatment should be discontinued if any deterioration in cardiac status occurs. Pioglitazone should not be used in patients with heart failure or a history of heart failure. Pioglitazone: risk of bladder cancer (July 2024)
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
pioglitazone hydrochloride is safe and effective in children. Who should not take pioglitazone tablets? See What is the most important information I should
Patients who have liver test abnormalities prior to initiation of pioglitazone tablets or who are found to have abnormal liver tests while taking pioglitazone tablets should be managed as described under Warnings and Precautions [see Warnings and Precautions (5.3)and Clinical Pharmacology (12.3)].
Who should not take pioglitazone tablets? See What is the most important information I should know about pioglitazone tablets? 35. Page 2. Do not take
The safety and efficacy of pioglitazone should be reviewed after 3 6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment. Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3 6 months, as above.
Comments